AU2001265346A1 - Artificial antigen presenting cells and methods of use thereof - Google Patents

Artificial antigen presenting cells and methods of use thereof

Info

Publication number
AU2001265346A1
AU2001265346A1 AU2001265346A AU6534601A AU2001265346A1 AU 2001265346 A1 AU2001265346 A1 AU 2001265346A1 AU 2001265346 A AU2001265346 A AU 2001265346A AU 6534601 A AU6534601 A AU 6534601A AU 2001265346 A1 AU2001265346 A1 AU 2001265346A1
Authority
AU
Australia
Prior art keywords
methods
presenting cells
antigen presenting
artificial antigen
artificial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001265346A
Inventor
Jean-Baptiste Latouche
Michel Sadelain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center filed Critical Sloan Kettering Institute for Cancer Research
Publication of AU2001265346A1 publication Critical patent/AU2001265346A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/46449Melanoma antigens
    • A61K39/464491Melan-A/MART
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656Adult fibroblasts
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5156Animal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539MHC-molecules, e.g. HLA-molecules
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/20Screening for compounds of potential therapeutic value cell-free systems
AU2001265346A 2000-06-02 2001-06-01 Artificial antigen presenting cells and methods of use thereof Abandoned AU2001265346A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20915700P 2000-06-02 2000-06-02
US60/209,157 2000-06-02
PCT/US2001/017981 WO2001094944A2 (en) 2000-06-02 2001-06-01 Artificial antigen presenting cells and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2001265346A1 true AU2001265346A1 (en) 2001-12-17

Family

ID=22777588

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001265346A Abandoned AU2001265346A1 (en) 2000-06-02 2001-06-01 Artificial antigen presenting cells and methods of use thereof

Country Status (5)

Country Link
US (1) US20020131960A1 (en)
EP (1) EP1287357A2 (en)
AU (1) AU2001265346A1 (en)
CA (1) CA2410510A1 (en)
WO (1) WO2001094944A2 (en)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
WO2002030964A2 (en) * 2000-10-10 2002-04-18 The Board Of Regents Of The University Of Oklahoma Comparative ligand mapping from mhc positive cells
EP1402064A4 (en) * 2001-05-30 2005-08-24 Gene Therapy Systems Inc Protein arrays and methods and systems for producing the same
AU2002322211A1 (en) * 2001-07-12 2003-01-29 Canvac Methods and compisitions for activation human t cells in vitro
US20070048329A1 (en) * 2002-11-07 2007-03-01 Rajiv Khanna Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
AU2003275767A1 (en) * 2002-11-07 2004-06-07 Johnson & Johnson Research Pty Limited A means of producing and utilising a population of disease specific cytotoxic T-lymphocytes
ATE538809T1 (en) * 2003-06-27 2012-01-15 Int Inst Cancer Immunology Inc METHOD FOR SELECTING APPROPRIATE PATIENTS FOR THE WT1 VACCINE
WO2007105954A1 (en) * 2006-03-16 2007-09-20 Leiden University Medical Center Methods for identifying t-cell epitopes associated with impaired peptide processing and applications of the identified epitopes
US20100068224A1 (en) * 2006-04-24 2010-03-18 Roberto Crea Method for Producing Viral Vaccine and Therapeutic Peptide Antigens
CN103374576A (en) 2007-03-05 2013-10-30 株式会社癌免疫研究所 Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
CN103429232B (en) 2010-11-12 2016-03-16 盖茨咨询和项目管理公司 The immunomodulating particle modified
CN103764826A (en) 2011-06-28 2014-04-30 株式会社癌免疫研究所 Receptor gene for peptide cancer antigen-specific t cell
TR201909998T4 (en) 2012-06-21 2019-07-22 Univ Northwestern Peptide conjugated particles.
CN114099461A (en) 2013-03-13 2022-03-01 onCOUR制药股份有限公司 Immunodified particles for the treatment of inflammation
CN105431523B (en) 2013-03-14 2020-08-21 约翰·霍普金斯大学 Nanoscale artificial antigen presenting cells
HUE047329T2 (en) 2013-08-13 2020-04-28 Univ Northwestern Peptide conjugated particles
US11400115B2 (en) 2014-04-23 2022-08-02 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
TWI751102B (en) 2014-08-28 2022-01-01 美商奇諾治療有限公司 Antibodies and chimeric antigen receptors specific for cd19
CN107002038B (en) 2014-09-17 2021-10-15 约翰·霍普金斯大学 Reagents and methods for identifying, enriching and/or expanding antigen-specific T cells
SG11201703203RA (en) 2014-10-20 2017-05-30 Juno Therapeutics Inc Methods and compositions for dosing in adoptive cell therapy
ES2805674T3 (en) 2014-11-05 2021-02-15 Juno Therapeutics Inc Methods for cell transduction and processing
ES2819553T3 (en) 2014-12-03 2021-04-16 Juno Therapeutics Inc Methods and compositions for adoptive cell therapy
MA41346A (en) 2015-01-12 2017-11-21 Juno Therapeutics Inc POST-TRANSCRIPTIONAL REGULATORY ELEMENTS OF MODIFIED HEPATITIS
ES2818103T3 (en) 2015-01-16 2021-04-09 Juno Therapeutics Inc ROR1-specific chimeric antigen receptors and antibodies
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
CN108174607A (en) 2015-05-29 2018-06-15 朱诺治疗学股份有限公司 For adjusting the composition and method of inhibition interaction in genetically engineered cell
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
RU2757135C2 (en) 2015-09-24 2021-10-11 АБВИТРО ЭлЭлСи Hiv antibody compositions and methods for their application
AU2016326734B2 (en) 2015-09-25 2022-07-07 Abvitro Llc High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences
MA45488A (en) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh CELL CULTURE PROCESSES, KITS AND APPARATUS
MA45489A (en) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh CELL CULTURE PROCESSES, ASSOCIATED KITS AND APPARATUS
BR112018008111A2 (en) 2015-10-22 2018-11-06 Juno Therapeutics Gmbh transduction methods, kits, agents and apparatus
MA44314A (en) 2015-11-05 2018-09-12 Juno Therapeutics Inc CHEMERICAL RECEPTORS CONTAINING TRAF-INDUCING DOMAINS, AND ASSOCIATED COMPOSITIONS AND METHODS
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
US11819516B2 (en) 2015-11-06 2023-11-21 The Regents Of The University Of Michigan Immunotherapy
WO2017096327A2 (en) 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Compositions and methods for reducing immune responses against cell therapies
AU2016363025B2 (en) 2015-12-03 2021-04-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
EP3384294B1 (en) 2015-12-04 2021-10-13 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
IL260296B2 (en) * 2016-01-04 2024-01-01 Cour Pharmaceuticals Dev Company Inc Particles encapsulating fusion proteins containing linked epitopes
WO2017161208A1 (en) 2016-03-16 2017-09-21 Juno Therapeutics, Inc. Methods for determining dosing of a therapeutic agent and related treatments
WO2017161212A1 (en) 2016-03-16 2017-09-21 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
AU2017238218B2 (en) 2016-03-22 2024-05-02 Seattle Children's Hospital (dba Seattle Children's Research Institute) Early intervention methods to prevent or ameliorate toxicity
MA44869A (en) 2016-05-06 2019-03-13 Editas Medicine Inc GENETICALLY MODIFIED CELLS AND THEIR MANUFACTURING PROCESSES
WO2017205846A1 (en) 2016-05-27 2017-11-30 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of genome-editing molecules
WO2017210689A1 (en) 2016-06-03 2017-12-07 Memorial Sloan-Kettering Cancer Center Adoptive cell therapies as early treatment options
MA45341A (en) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res METHODS FOR TREATING B-LYMPHOCYTE MALIGNITIES USING ADOPTIVE CELL THERAPY
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
EP3475446A1 (en) 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
JP7295795B2 (en) 2016-07-29 2023-06-21 ジュノー セラピューティクス インコーポレイテッド Immunomodulatory Polypeptides and Related Compositions and Methods
JP7062640B2 (en) 2016-07-29 2022-05-06 ジュノー セラピューティクス インコーポレイテッド Anti-idiotype antibody against anti-CD19 antibody
WO2018023094A1 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Methods for assessing the presence or absence of replication competent virus
WO2018049420A1 (en) 2016-09-12 2018-03-15 Juno Therapeutics, Inc. Perfusion bioreactor bag assemblies
US20190298771A1 (en) 2016-09-28 2019-10-03 Atossa Genetics Inc. Methods of adoptive cell therapy
MX2019003768A (en) 2016-10-03 2019-06-24 Juno Therapeutics Inc Hpv-specific binding molecules.
CN110381963A (en) 2016-10-13 2019-10-25 朱诺治疗学股份有限公司 It is related to the immunotherapy method and composition of tryptophan metabolic pathway regulator
WO2018093591A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
JP2019532997A (en) 2016-11-03 2019-11-14 ジュノー セラピューティクス インコーポレイテッド Combination therapy with T cell therapy and BTK inhibitor
BR112019011065A2 (en) 2016-12-03 2019-10-01 Juno Therapeutics Inc methods for determining car cell dosage
CA3045339A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
KR20190104529A (en) 2016-12-03 2019-09-10 주노 쎄러퓨티크스 인코퍼레이티드 Modulation of CAR-T Cells
JP2019536461A (en) 2016-12-05 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Production of engineered cells for adoptive cell therapy
CN110691792A (en) 2017-01-10 2020-01-14 朱诺治疗学股份有限公司 Epigenetic analysis of cell therapies and related methods
WO2018134691A2 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
SG11201907580SA (en) 2017-02-17 2019-09-27 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
CN110582287A (en) 2017-02-27 2019-12-17 朱诺治疗学股份有限公司 Compositions, articles of manufacture, and methods relating to administration in cell therapy
CN110913690A (en) 2017-03-14 2020-03-24 朱诺治疗学股份有限公司 Method for cryogenic storage
MX2019012017A (en) 2017-04-07 2020-02-12 Juno Therapeutics Inc Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods.
US11796534B2 (en) 2017-04-14 2023-10-24 Juno Therapeutics, Inc. Methods for assessing cell surface glycosylation
CN110891967A (en) 2017-04-18 2020-03-17 富士胶片细胞动力公司 Antigen-specific immune effector cells
NZ758485A (en) 2017-04-27 2024-02-23 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
DK3618842T3 (en) 2017-05-01 2024-01-02 Juno Therapeutics Inc COMBINATION OF A CELL THERAPY AND AN IMMUNOMODULATING COMPOUND
KR20200054160A (en) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 Preparation and method of articles for treatment with adoptive cell therapy
EP3631468A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
IL271618B1 (en) 2017-06-20 2024-02-01 Inst Curie Immune cells defective for suv39h1
KR20200019231A (en) 2017-06-22 2020-02-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Method for producing regulatory immune cells and uses thereof
CA3067602A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
SG11202000606TA (en) 2017-07-29 2020-02-27 Juno Therapeutics Inc Reagents for expanding cells expressing recombinant receptors
ES2959953T3 (en) 2017-08-09 2024-02-29 Juno Therapeutics Inc Methods for producing genetically modified cellular compositions and related compositions
KR20200046045A (en) 2017-08-09 2020-05-06 주노 쎄러퓨티크스 인코퍼레이티드 Methods and compositions for making genetically engineered cells
MA50057A (en) 2017-09-01 2020-07-08 Juno Therapeutics Inc GENE EXPRESSION AND ASSESSMENT OF A RISK OF DEVELOPING TOXICITY FOLLOWING CELL THERAPY
US20200292526A1 (en) 2017-09-07 2020-09-17 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
CN109517820B (en) 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 gRNA of target HPK1 and HPK1 gene editing method
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
CN111527209A (en) 2017-11-01 2020-08-11 爱迪塔斯医药股份有限公司 Methods, compositions, and components of CRISPR-CAS9 editing TGFBR2 in T cells for immunotherapy
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
MA50859A (en) 2017-11-01 2020-09-09 Celgene Corp PROCESS FOR THE PRODUCTION OF A COMPOSITION OF T LYMPHOCYTES
JP7357626B2 (en) 2017-11-01 2023-10-06 ジュノー セラピューティクス インコーポレイテッド Process for producing therapeutic compositions of engineered cells
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CN111886012A (en) 2017-11-06 2020-11-03 朱诺治疗学股份有限公司 Combination of cell therapy with gamma secretase inhibitors
KR20200079312A (en) 2017-11-06 2020-07-02 에디타스 메디신, 인코포레이티드 CRISPR-CAS9 editing method, composition and components of CBLB in T cells for immunotherapy
CN111556789A (en) 2017-11-10 2020-08-18 朱诺治疗学股份有限公司 Closed system cryogenic vessel
MA51210A (en) 2017-12-01 2020-10-07 Juno Therapeutics Inc METHODS FOR DOSING AND MODULATING GENETICALLY MODIFIED CELLS
SG11202005217VA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Phenotypic markers for cell therapy and related methods
CA3084445A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
US20210207080A1 (en) 2017-12-08 2021-07-08 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
CN112204048A (en) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 anti-CCT5 binding molecules and methods of use thereof
US11919937B2 (en) 2018-01-09 2024-03-05 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
EP3746569A1 (en) 2018-01-31 2020-12-09 Juno Therapeutics, Inc. Methods and reagents for assessing the presence or absence of replication competent virus
CN111971059A (en) 2018-01-31 2020-11-20 细胞基因公司 Combination therapy using adoptive cell therapy and checkpoint inhibitors
EP3762012A1 (en) 2018-03-09 2021-01-13 Ospedale San Raffaele S.r.l. Il-1 antagonist and toxicity induced by cell therapy
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
MX2020010460A (en) 2018-04-05 2021-01-29 Juno Therapeutics Inc T cell receptors and engineered cells expressing same.
US20210121466A1 (en) 2018-05-03 2021-04-29 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
MX2021001523A (en) 2018-08-09 2021-05-27 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof.
EA202190469A1 (en) 2018-08-09 2021-06-28 Джуно Терапьютикс, Инк. METHODS FOR ASSESSMENT OF INTEGRATED NUCLEIC ACIDS
EP3844266A1 (en) 2018-08-28 2021-07-07 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
BR112021004261A2 (en) 2018-09-11 2021-05-25 Juno Therapeutics Inc methods for mass spectrometric analysis of genetically modified cell compositions
BR112021008133A2 (en) 2018-10-31 2021-10-05 Juno Therapeutics Gmbh METHODS FOR SELECTION AND STIMULATION OF CELLS AND DEVICES FOR THE SAME
JP2022512917A (en) 2018-11-01 2022-02-07 ジュノー セラピューティクス インコーポレイテッド Treatment method using a chimeric antigen receptor specific for B cell maturation antigen
SG11202104183RA (en) 2018-11-06 2021-05-28 Juno Therapeutics Inc Process for producing genetically engineered t cells
BR112021008963A2 (en) 2018-11-08 2021-09-14 Neximmune, Inc. T-CELL COMPOSITIONS WITH IMPROVED PHENOTYPIC PROPERTIES
KR20210111247A (en) 2018-11-08 2021-09-10 주노 쎄러퓨티크스 인코퍼레이티드 Methods and Combinations for Treatment and Modulation of T Cells
CN113271963A (en) 2018-11-16 2021-08-17 朱诺治疗学股份有限公司 Methods of administering engineered T cells for treatment of B cell malignancies
EP3883955A1 (en) 2018-11-19 2021-09-29 Board of Regents, The University of Texas System A modular, polycistronic vector for car and tcr transduction
CA3121027A1 (en) 2018-11-28 2020-06-04 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
KR20210096648A (en) 2018-11-29 2021-08-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Methods and uses thereof for ex vivo expansion of natural killer cells
CA3120869A1 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
SG11202105380RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
WO2020120649A1 (en) 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
CN113365660A (en) 2019-01-29 2021-09-07 朱诺治疗学股份有限公司 Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase-like orphan receptor 1(ROR1)
KR20220016474A (en) 2019-05-01 2022-02-09 주노 쎄러퓨티크스 인코퍼레이티드 Cells expressing chimeric receptors from modified CD247 loci, related polynucleotides and methods
KR20220016475A (en) 2019-05-01 2022-02-09 주노 쎄러퓨티크스 인코퍼레이티드 Cells, Associated Polynucleotides and Methods Expressing Recombinant Receptors at the Modified TFTFR2 Locus
JP2022535380A (en) 2019-06-07 2022-08-08 ジュノー セラピューティクス インコーポレイテッド Automated T cell culture
CA3142361A1 (en) 2019-06-12 2020-12-17 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
EP4003407A1 (en) 2019-07-23 2022-06-01 Mnemo Therapeutics Immune cells defective for suv39h1
CN114555112A (en) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 Combination therapy of T cell therapy and ZESTE enhancer homolog 2(EZH2) inhibitors and related methods
US20220392613A1 (en) 2019-08-30 2022-12-08 Juno Therapeutics, Inc. Machine learning methods for classifying cells
CN114746109A (en) 2019-09-02 2022-07-12 居里研究所 Immunotherapy targeting tumor neoantigenic peptides
US20230081117A1 (en) 2019-09-09 2023-03-16 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
EP4048304A1 (en) 2019-10-22 2022-08-31 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
AU2020377043A1 (en) 2019-10-30 2022-06-02 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
BR112022007548A2 (en) 2019-11-07 2022-07-12 Juno Therapeutics Inc COMBINATION OF A T-CELL THERAPY AND (S)-3-[4-(4-MORPHOLIN-4-YLMETHYL-BENZYLOXY)-1-OXO-1,3-DI-HYDRO-ISOINDOL-2-YL]-PIPERIDINE-2 ,6-DIONA
WO2021113770A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
BR112022010627A2 (en) 2019-12-06 2022-08-16 Juno Therapeutics Inc ANTI-IDIOTYPIC ANTIBODIES TO BINDING DOMAINS TARGETED BY BCMA AND RELATED COMPOSITIONS AND METHODS
WO2021113780A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
BR112022014501A2 (en) 2020-01-24 2022-09-20 Juno Therapeutics Inc METHODS FOR DOSING AND TREATMENT OF FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA IN ADOPTIVE CELL THERAPY
US20230090117A1 (en) 2020-01-28 2023-03-23 Juno Therapeutics, Inc. Methods for t cell transduction
CA3169672A1 (en) 2020-02-12 2021-08-19 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
WO2021163389A1 (en) 2020-02-12 2021-08-19 Juno Therapeutics, Inc. Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
BR112022020333A2 (en) 2020-04-10 2022-11-22 Juno Therapeutics Inc METHODS AND USES RELATED TO CELL THERAPY DESIGNED WITH A CHIMERIC ANTIGEN RECEPTOR THAT TARGETS B CELL MATURATION ANTIGEN
EP4149952A1 (en) 2020-05-12 2023-03-22 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
JP2023528215A (en) 2020-05-13 2023-07-04 ジュノー セラピューティクス インコーポレイテッド Methods of identifying features associated with clinical response and uses thereof
KR20230022868A (en) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 Method for producing donor-batch cells expressing a recombinant acceptor
US20230212256A1 (en) 2020-05-21 2023-07-06 Board Of Regents, The University Of Texas System T cell receptors with vgll1 specificity and uses thereof
EP4171616A1 (en) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
CN116096864A (en) 2020-07-30 2023-05-09 居里研究所 SOCS1 deficient immune cells
WO2022029660A1 (en) 2020-08-05 2022-02-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
KR20230151513A (en) 2021-01-11 2023-11-01 사나 바이오테크놀로지, 인크. Uses of CD8 Targeting Viral Vectors
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
CA3213002A1 (en) 2021-03-11 2022-09-15 Institut Curie Transmembrane neoantigenic peptides
WO2022189639A1 (en) 2021-03-11 2022-09-15 Mnemo Therapeutics Tumor neoantigenic peptides and uses thereof
KR20230172630A (en) 2021-03-11 2023-12-22 므네모 테라퓨틱스 Tumor Neoantigenic Peptide
WO2022204070A1 (en) 2021-03-22 2022-09-29 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
CN117321200A (en) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 Method for assessing efficacy of viral vector particles
JP2024513054A (en) 2021-03-29 2024-03-21 ジュノー セラピューティクス インコーポレイテッド Combination of CAR T cell therapy and immunomodulatory compounds for the treatment of lymphoma
BR112023019847A2 (en) 2021-03-29 2023-11-07 Juno Therapeutics Inc METHODS FOR DOSING AND TREATMENT WITH A COMBINATION OF A CHECKPOINT INHIBITOR THERAPY AND A CAR T CELL THERAPY
JP2024517863A (en) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Methods for stimulating and transducing cells
TW202321457A (en) 2021-08-04 2023-06-01 美商薩那生物科技公司 Use of cd4-targeted viral vectors
WO2023014922A1 (en) 2021-08-04 2023-02-09 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
WO2023105000A1 (en) 2021-12-09 2023-06-15 Zygosity Limited Vector
TW202342498A (en) 2021-12-17 2023-11-01 美商薩那生物科技公司 Modified paramyxoviridae fusion glycoproteins
TW202342757A (en) 2021-12-17 2023-11-01 美商薩那生物科技公司 Modified paramyxoviridae attachment glycoproteins
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
WO2023139269A1 (en) 2022-01-21 2023-07-27 Mnemo Therapeutics Modulation of suv39h1 expression by rnas
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023178348A1 (en) 2022-03-18 2023-09-21 The Regents Of The University Of Colorado, A Body Corporate Genetically engineered t-cell co-receptors and methods of use thereof
WO2023180552A1 (en) 2022-03-24 2023-09-28 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023196921A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Granzyme expressing t cells and methods of use
WO2023196933A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Chimeric antigen receptor t cells and methods of use thereof
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024006960A1 (en) 2022-06-29 2024-01-04 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
WO2024044779A2 (en) 2022-08-26 2024-02-29 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU774442B2 (en) * 1998-10-20 2004-06-24 Salvatore Albani Methods for isolation, quantification, characterization and modulation of antigen-specific T cells

Also Published As

Publication number Publication date
EP1287357A2 (en) 2003-03-05
US20020131960A1 (en) 2002-09-19
WO2001094944A2 (en) 2001-12-13
WO2001094944A3 (en) 2002-08-22
CA2410510A1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
AU2001265346A1 (en) Artificial antigen presenting cells and methods of use thereof
AU2001259215A1 (en) Human anti-cd40 antibodies and methods of making and using same
AU2003287400A1 (en) Implantable artificial partition and methods of use
AU2001277172A1 (en) Bstp-trans protein and related reagents and methods of use thereof
AU4055600A (en) Impaction substrate and methods of use
AU2001283492A1 (en) Methods of patterning protein and cell adhesivity
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002322211A1 (en) Methods and compisitions for activation human t cells in vitro
WO2003083062A8 (en) Anti-il-tif antibodies and methods of using in inflammation
AU2002324965A1 (en) Artificial kidney and methods of using same
AU2002211183A1 (en) Prosthetic construct and methods for its manufacture and use
AU2001278011A1 (en) Bstp-ecg1 protein and related reagents and methods of use thereof
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2002230459A1 (en) Cell culture apparatus and methods of use
AU2001255696A1 (en) Telomerase inhibitors and methods of their use
AU4014700A (en) Tuberculosis antigens and methods of use therefor
AU2001261375A1 (en) Human caspase-12 materials and methods
AU2001217686A1 (en) Method of establishing cultures of human dendritic cells and use thereof
AU2003294575A1 (en) Implant anchor and methods of use
AU3501700A (en) Human endokine alpha and methods of use
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
AU2003276844A1 (en) Formulations of modified antibodies and methods of making the same
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001245506A1 (en) Injectable bio-compatible material and methods of use
AU1417701A (en) Soluble t cell receptor protein and method of constructing the same